CutKilo operates as a UK-based medical weight loss program founded by Dr. Emil Gadimali, a physician practicing on Harley Street in London. The service centers on medically supervised treatment using Mounjaro, a prescription medication containing tirzepatide that's administered through weekly self-injections. Dr. Gadimali brings experience from various London NHS hospitals including Chelsea and Westminster, UCLH, and Ealing Hospital, along with medical training from King's College London and an MBA from Imperial College London.

The treatment revolves around GLP-1/GIP medication that's been used for over a decade in diabetes management before being applied to weight loss. Tirzepatide, the active ingredient in Mounjaro, consists of 39 amino acids forming a synthetic peptide that's roughly 90% identical to two naturally occurring hormones in the body. The medication works on gut-brain signals to reduce appetite and extend feelings of fullness after eating. Clinical data shows patients can lose up to 25% of their body weight, with 95% experiencing at least 5% weight loss.

The enrollment process starts with a five-minute online consultation where applicants provide health history information. CutKilo reviews applications within 24 hours, and approved candidates receive a one-to-one video call with the doctor to create a tailored prescription plan. Once approved, patients receive their Mounjaro pen by post—a pre-filled injector containing four weekly doses that patients administer themselves. The program includes educational videos teaching new habits and lifestyle adjustments alongside the medication.

Support comes from multiple healthcare professionals rather than just medication delivery. Each patient gets a one-hour consultation with Hanna Baldursdottir, the in-house dietitian, included in their pricing. Dr. Gadimali provides unlimited touchpoints throughout treatment, meaning patients aren't restricted to scheduled check-ins when questions arise. A personal health coach offers daily availability through chat and video for motivation, practical advice, or simply listening when patients need someone to talk to about their progress.

Monthly pricing varies by dosage strength, starting at £260 for 2.5mg and scaling up to £380 for 15mg. The program isn't structured as a subscription—instead, CutKilo emails a short check-in form about 2.5 weeks after each order. Patients complete this form to report progress and decide whether to increase dosage, maintain the current level, or discontinue treatment. This approach gives patients control over continuation without automatic recurring charges or cancellation hassles.

Communication happens through WhatsApp, telephone, or video call depending on patient preference and urgency. The team connects patients with the appropriate healthcare professional based on whether they need medical guidance from the doctor, nutritional advice from the dietitian, or general support from the health coach. This multi-channel accessibility aims to remove barriers that might prevent patients from seeking help when they hit challenges or have questions about side effects, dosing schedules, or dietary adjustments.

The medication addresses what the program calls "food noise"—persistent thoughts about eating that many people trying to lose weight experience constantly. Beyond weight reduction, Mounjaro has been shown to lower cardiovascular disease risk by reducing blood pressure, cholesterol, and blood sugar levels. These metabolic improvements matter particularly for patients whose weight affects their heart health or diabetes risk. The long-term treatment model recognizes that maintaining weight loss requires ongoing support rather than short-term intervention.

CutKilo positions itself against traditional weight loss approaches that rely on calorie counting, food restriction, or elimination diets. The program emphasizes that restrictive diets often slow metabolism and increase hunger, leading to weight regain once people return to normal eating patterns. The medical intervention targets hormonal balance and appetite regulation at a physiological level rather than depending purely on willpower and dietary compliance. Dr. Gadimali's background includes serving as a trustee at SarcoidosisUK and advising pharmaceutical and biotech companies, bringing industry knowledge to the clinical practice of weight management.

---